Results from the PEARL-II study show treatment-experienced patients with hepatitis C genotype 1b achieved SVR rates of greater than 96% when treated with a combination of ABT 450 with ritonavir, co-formulated with ombitasvir and dasabuvir, without the need for ribavirin.
Patients with celiac disease treated with larazotide acetate experienced improvements in GI symptoms and non-GI symptoms such as headache and fatigue, as well as significant reductions in the number of symptomatic days.
An all-oral, ribavirin-free, interferon-free combination of three direct-acting antiviral agents that had achieved sustained virologic response in 92% of patients with chronic HCV genotype 1 infection has demonstrated even greater response in patients with genotype 4 infection.
Treatment with an 8-week regimen of combination sofosbuvir plus ledipasvir with or without ribavirin produced sustained virologic response rates (SVR) similar to those achieved with a 12-week regimen in non-cirrhotic, previously untreated, genotype 1 hepatitis C patients, according to results from the ION-3 trial.
Patients in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial who were also treated with statins experienced a significant decrease in time to histological disease progression compared to patients who did not receive statin treatment.
Within the next two years, treatments for hepatitis C with 95% cure rates that are all-oral, interferon-free, and effective within 12 weeks or less with negligible side effects will be readily available.
Phase 2 study results show patients with ulcerative colitis treated with an investigational oral compound achieved higher rates of remission, reduced rectal bleeding, and increased mucosal healing compared to patients who received placebo.